Topiramate
Product Images NDC 70934-022

4 FDA label images from Denton Pharma, Inc. Dba Northwind Pharmaceuticals · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 70934-022). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Denton Pharma, Inc. Dba Northwind Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

70934 022 60 Rev A 07 19

70934 022 60 Rev A 07 19
Topiramate Tablets USP 25 mg in a bottle label from Denton Pharma, Inc. DBA Northwind Pharmaceuticals. The label states the package contains 60 tablets, for prescription use only. Storage instructions and warnings about controlled room temperature and child safety are included. The label also features barcodes and manufacturing details.*
FDA Label Image

Chemical-structure (Chemical Structure)

Chemical-structure (Chemical Structure)
Chemical structure of Topiramate, showing its distinctive rings and functional groups including sulfonamide and multiple ether linkages.*
FDA Label Image

Figure-1jpg (Figure 1)

Figure-1jpg (Figure 1)
A Kaplan-Meier curve chart showing cumulative rates for time to first seizure over 500 days. Two dosage groups of Topiramate, 50 mg/day and 400 mg/day, are compared with distinct lines representing seizure occurrence rates over time. The chart includes sample sizes (N=234 for 50 mg/day and N=236 for 400 mg/day) and a statistical p-value of 0.0002.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A bar chart showing the change from baseline to double-blind phase in average monthly migraine period rate with Topiramate at doses of 50 mg/day, 100 mg/day, and 200 mg/day compared to placebo. Data is presented for two studies (Study 10 and Study 11), with bars indicating negative change values and significance levels noted (p<0.010, p<0.001) for higher doses.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.